RE:RE:RE:RE:RE:RE:Zero enrollment updateThanks for your response hmmmmmm. We do agree then that Baxter is the expectant suitor and their time frame is approx this year (2023). Don't forget we already have credit for the cases done through the prior trial. Tigris is a confirmatory trial and they have at least 52 completed cases that are greatly exceeding expectations. To get to 90 they need 38 more of which there must be some done but not yet disclosed. Even you would agree we're not very far from the corner where the big Baxter limousine would pick us up to take us to riches. I see the risk of the remaining 38 cases not "exceeding expectations" as very remote. You pose a very interesting question which is what would Baxter pay for an unfinished PMX trial compared to an FDA approved PMX. My answer is yes it's a fraction but not a miniscule fraction. I do think MM is correct with his $8 per share value for the company with FDA approval for PMX. Let's assume we don't have that at the end of the year. Baxter could offer KidneyCo paper at the end of 2023 valued at 50% (say $4 per Spectral share) plus CONTINGENT CONSIDERATION equal to say $4 per share less costs to complete plus a decent return for the effort - say $2 per share on success. That fraction then is sure 50% up front with a final of say 25% contingent.
I agree with you it's not an acceptable outcome. But if you're stuck in the mud you do everything to maximize your well being and your vehicle's well being even if you don't get there 100%. Put another way you take 75% and grumble about the 25% lost because of others incompetence.
Why should one reward others for not performing? That's a rhetorical question that our self appointed shareholder activist was going to pose to management and the BOD - and bring in the OSC if proper disclosure wasn't done by Spectral. So far no feedback has been provided. The simple question still stands - was the management, the BOD and the OSC approached. If no then say so. if yes what were the responses?